Medical Journals

Oral Administration of S-nitroso-n-acetylcysteine Prevents the Onset of Non Alcoholic Fatty Liver Disease in Rats.

Authors:
  • de Oliveira Claudia P M S
  • Simplicio Fernanda I
  • de Lima Vicencia M R
  • Yuahasi Katia
  • Lopasso Fabio P
  • Alves Venancio A F
  • Abdalla Dulcineia S P
  • Carrilho Flair J
  • Laurindo Francisco R M
  • de Oliveira Marcelo G

From: Instituto de Quimica, UNICAMP, CP 6154, CEP 13083-970, Campinas, São Paulo, Brazil.

World journal of gastroenterology : WJG

  • Publish Date: Mar 2006
  • ISSN: 1007-9327
  • Volume: 12
  • Issue: 12
  • Pages: 1905-11
  • Medium: Print
  • Language: English
  • Citation (JAMA): de Oliveira Claudia P M S, Simplicio Fernanda I, de Lima Vicencia M R, et al. Oral Administration of S-nitroso-n-acetylcysteine Prevents the Onset of Non Alcoholic Fatty Liver Disease in Rats.. World J. Gastroenterol. Mar 2006;12:1905-11

Abstract

AIM: To evaluate the potential of S-nitroso-N-acetylcysteine (SNAC) in inhibition of lipid peroxidation and the effect of oral SNAC administration in the prevention of nonalcoholic fatty liver disease (NAFLD) in an animal model. METHODS: NAFLD was induced in Wistar male rats by choline-deficient diet for 4 wk. SNAC-treated animals (n=6) (1.4 mg/kg per day of SNAC, orally) were compared to 2 control groups: one (n=6) received PBS solution and the other (n=6) received NAC solution (7 mg/kg per day). Histological variables were semiquantitated with respect to macro and microvacuolar fat changes, its zonal distribution, foci of necrosis, portal and perivenular fibrosis, and inflammatory infiltrate with zonal distribution. LOOHs from samples of liver homogenates were quantified by HPLC. Nitrate levels in plasma of portal vein were assessed by chemiluminescence. Aqueous low-density lipoprotein (LDL) suspensions (200 microg protein/mL) were incubated with CuCl(2) (300 micromol/L) in the absence and presence of SNAC (300 micromol/L) for 15 h at 37 degree Celsius. Extent of LDL oxidation was assessed by fluorimetry. Linoleic acid (LA) (18.8 micromol/L) oxidation was induced by soybean lipoxygenase (SLO) (0.056 micromol/L) at 37 degree Celsius in the presence and absence of N-acetylcysteine (NAC) and SNAC (56 and 560 micromol/L) and monitored at 234 nm. RESULTS: Animals in the control group developed moderate macro and microvesicular fatty changes in periportal area. SNAC-treated animals displayed only discrete histological alterations with absence of fatty changes and did not develop liver steatosis. The absence of NAFLD in the SNAC-treated group was positively correlated with a decrease in the concentration of LOOH in liver homogenate, compared to the control group (0.7+/-0.2 nmol/mg vs 3.2+/-0.4 nmol/mg protein, respectively, P<0.05), while serum levels of aminotransferases were unaltered. The ability of SNAC in preventing lipid peroxidation was confirmed in in vitro experiments using LA and LDL as model substrates. CONCLUSION: Oral administration of SNAC prevents the onset of NAFLD in Wistar rats fed with choline-deficient diet. This effect is correlated with the ability of SNAC to block the propagation of lipid peroxidation in vitro and in vitro.

Mesh Headings (Keywords): Acetylcysteine, Administration, Oral, Animals, Disease Models, Animal, Fatty Liver, Lipid Peroxidation, Liver, Male, Necrosis, Nitrates, Rats, Rats, Wistar, Transaminases


Check for Full Text / PubMed Unique Identifier (PMID): 16609997


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.